Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Releases Earnings Results, Misses Expectations By $0.10 EPS

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) posted its quarterly earnings data on Tuesday. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.10), Zacks reports. Bayer Aktiengesellschaft had a positive return on equity of 16.96% and a negative net margin of 2.74%. The company had revenue of $10.96 billion during the quarter. Bayer Aktiengesellschaft updated its FY 2024 guidance to 5.610-6.045 EPS.

Bayer Aktiengesellschaft Stock Performance

Shares of BAYRY traded down $0.87 during mid-day trading on Wednesday, hitting $5.58. The company’s stock had a trading volume of 4,104,154 shares, compared to its average volume of 1,120,233. Bayer Aktiengesellschaft has a fifty-two week low of $5.49 and a fifty-two week high of $11.33. The firm has a 50-day moving average price of $7.44 and a 200 day moving average price of $7.43. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86 and a current ratio of 1.27.

Analyst Upgrades and Downgrades

Separately, Bank of America raised Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a report on Friday, September 6th. One analyst has rated the stock with a sell rating and eight have issued a hold rating to the company’s stock. Based on data from MarketBeat.com, Bayer Aktiengesellschaft presently has an average rating of “Hold”.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.